

MEDICAID POLICY CHANGE

IMMINENT PERIL JUSTIFICATION

September 3, 2024

GLP-1 PRIOR AUTHORIZATION CRITERIA FOR MAXIMUM DOSE, QUANTITY LIMIT AND THERAPEUTIC DUPLICATION

POLICY CHANGE:

Terminate the Point of Sale (POS) override for doses higher than the maximum dose, quantities higher than the set quantity limits and for therapeutic duplication. Prior authorization will be required to override these edits.

JUSTIFICATION:

This is necessary in an effort to ensure appropriate utilization for the GLP-1s.

EFFECTIVE DATE:

September 4, 2024